Paula Green Sells 291 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 291 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $41.68, for a total transaction of $12,128.88. Following the transaction, the senior vice president now owns 130,621 shares in the company, valued at approximately $5,444,283.28. This represents a 0.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Paula Green also recently made the following trade(s):

• On Thursday, March 6th, Paula Green sold 918 shares of Twist Bioscience stock. The shares were sold at an average price of $40.91, for a total value of $37,555.38.
• On Monday, February 3rd, Paula Green sold 1,259 shares of Twist Bioscience stock. The shares were sold at an average price of $49.35, for a total value of $62,131.65.
• On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total value of $7,294.40.

Twist Bioscience Stock Down 1.5 %

Shares of TWST stock opened at $44.25 on Wednesday. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The firm has a market cap of $2.64 billion, a PE ratio of -13.09 and a beta of 2.15. The stock has a 50 day moving average of $45.45 and a 200-day moving average of $45.36.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same period in the prior year, the firm earned ($0.75) EPS. The business’s revenue was up 24.1% on a year-over-year basis. On average, equities analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Twist Bioscience by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock valued at $269,860,000 after acquiring an additional 189,791 shares in the last quarter. ARK Investment Management LLC raised its stake in shares of Twist Bioscience by 4.4% in the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock valued at $260,040,000 after purchasing an additional 237,772 shares in the last quarter. State Street Corp lifted its position in Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares during the period. Thrivent Financial for Lutherans boosted its stake in Twist Bioscience by 54.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock worth $69,972,000 after buying an additional 532,040 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Twist Bioscience by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company’s stock valued at $63,895,000 after buying an additional 6,908 shares during the period.

Analyst Upgrades and Downgrades

TWST has been the subject of several recent research reports. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Wolfe Research assumed coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Robert W. Baird increased their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, February 4th. Finally, Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus target price of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.